Clinical Trial

Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL

Name: Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL — clinical trial record (NCT07072208)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

To evaluate the efficacy and safety of the Pro-Pola （Pomalidomide, rituximab, orelabrutinib and polatuzumab vedotin) regimen in elderly patients (aged ≥70 years) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

Trial Details

NCT Number	NCT07072208
Lead Sponsor	The First Affiliated Hospital of Soochow University
Conditions	Diffuse Large B-Cell Lymphoma
Enrollment	43 participants
Start Date	2024-11-01
Primary Completion	2027-05-01 (estimated)
Study Completion	2027-05-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-18